Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>The English winemaker reports results for the FY period to 31 December 2025. There is a 19% increase in revenue to £19.4m, with a small decline in gross margin to 47.1% from 48.4%.</li>
<li>The EBITDA is £3.75m against £2.98m, and PBT is £0.469k compared to a £1,400k loss in the prior period. Stocks increased 15% to £30.6m and net debt increased to £12.4m from £9.4m.</li>
<li>The headroom on the £20m revolving credit facility remains in place, with an accordion option to extend the facility to £30m. </li>
</ul>


The English winemaker reports results for the FY period to 31 December 2025. There is a 19% increase in revenue to £19.4m, with a small decline in gross margin to 47.1% from 48.4%.
The EBITDA is £3.75m against £2.98m, and PBT is £0.469k compared to a £1,400k loss in the prior period. Stocks increased 15% to £30.6m and net debt increased to £12.4m from £9.4m.
The headroom on the £20m revolving credit facility remains in place, with an accordion option to extend the facility to £30m. 


하이브리단 소형주 특혜: 2026년 4월 29일

Futura Medical

하이브리단 소형주 특혜: 2026년 4월 29일